NASDAQ:GNCA - Genocea Biosciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: 4,738.71 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.06
▼ -0.01 (-13.89%)

This chart shows the closing price for GNCA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genocea Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNCA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNCA

Analyst Price Target is $3.00
▲ +4,738.71% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Genocea Biosciences in the last 3 months. The average price target is $3.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 4,738.71% upside from the last price of $0.06.

This chart shows the closing price for GNCA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Genocea Biosciences. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/3/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/27/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/29/2022HC WainwrightDowngradeBuy ➝ NeutralHigh
4/29/2022Stifel NicolausDowngradeBuy ➝ HoldHigh
4/11/2022Robert W. BairdLower Price Target$8.00 ➝ $3.00High
5/3/2021Robert W. BairdReiterated RatingBuy$8.00Medium
4/6/2021SVB LeerinkBoost Price TargetOutperform$5.00 ➝ $6.00Medium
2/11/2021Needham & Company LLCLower Price TargetBuy$7.00 ➝ $6.00Low
7/30/2020Needham & Company LLCLower Price TargetBuy$10.00 ➝ $7.00Low
7/23/2020HC WainwrightLower Price TargetBuy$32.00 ➝ $9.00Low
7/20/2020Needham & Company LLCReiterated RatingBuy$10.00High
7/5/2020SVB LeerinkReiterated RatingOutperform$5.00High
6/23/2020HC WainwrightReiterated RatingBuy$32.00Medium
5/29/2020HC WainwrightReiterated RatingBuy$32.00Medium
5/12/2020Needham & Company LLCReiterated RatingBuy$10.00High
4/30/2020HC WainwrightReiterated RatingBuy$32.00High
4/30/2020Needham & Company LLCInitiated CoverageBuy$10.00High
11/15/2019SVB LeerinkInitiated CoverageOutperform$7.00High
11/11/2019HC WainwrightReiterated RatingBuyHigh
10/24/2019Needham & Company LLCReiterated RatingBuy$10.00Low
9/30/2019HC WainwrightSet Price TargetBuy$32.00Low
9/30/2019Needham & Company LLCReiterated RatingBuy$16.00High
7/25/2019HC WainwrightReiterated RatingBuy$42.00 ➝ $32.00Low
7/8/2019Stifel NicolausInitiated CoverageBuy ➝ BuyMedium
3/1/2019Needham & Company LLCReiterated RatingBuy ➝ BuyHigh
2/28/2019HC WainwrightSet Price TargetBuy$5.00 ➝ $5.75Low
11/27/2018HC WainwrightSet Price TargetBuy$5.00Low
11/7/2018HC WainwrightSet Price TargetBuy$5.00Medium
11/1/2018HC WainwrightReiterated RatingBuy$5.00High
8/2/2018HC WainwrightSet Price TargetBuy$5.00Low
5/10/2018HC WainwrightSet Price TargetBuy$5.00Low
4/30/2018HC WainwrightSet Price TargetBuy$5.00Medium
3/11/2018Cantor FitzgeraldSet Price TargetBuy$5.00Low
3/8/2018HC WainwrightInitiated CoverageBuy$5.00Low
3/5/2018Cantor FitzgeraldInitiated CoverageOverweight$5.00High
2/12/2018Robert W. BairdInitiated CoverageOutperform$3.00High
2/6/2018Needham & Company LLCUpgradeHold ➝ Buy$3.00High
11/2/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00N/A
9/26/2017Needham & Company LLCDowngradeBuy ➝ HoldHigh
9/26/2017CowenReiterated RatingBuy$10.00High
9/25/2017Stifel NicolausDowngradeBuy ➝ Hold$15.00 ➝ $2.50High
7/25/2017CowenReiterated RatingOutperform$40.00High
7/25/2017Piper Jaffray CompaniesReiterated RatingOverweight$17.00 ➝ $18.00High
7/24/2017Needham & Company LLCUpgradeHold ➝ Buy$12.00High
(Data available from 5/28/2017 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/29/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/28/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
5/28/2022

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Genocea Biosciences logo
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.06
Low: $0.06
High: $0.07

50 Day Range

MA: $0.58
Low: $0.06
High: $1.38

52 Week Range

Now: $0.06
Low: $0.06
High: $2.68

Volume

17,602,570 shs

Average Volume

4,457,767 shs

Market Capitalization

$3.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Genocea Biosciences?

The following Wall Street research analysts have issued research reports on Genocea Biosciences in the last year: HC Wainwright, Robert W. Baird, Stifel Nicolaus, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for GNCA.

What is the current price target for Genocea Biosciences?

0 Wall Street analysts have set twelve-month price targets for Genocea Biosciences in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 4,738.7%.
View the latest price targets for GNCA.

What is the current consensus analyst rating for Genocea Biosciences?

Genocea Biosciences currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GNCA, but not buy more shares or sell existing shares.
View the latest ratings for GNCA.

How do I contact Genocea Biosciences' investor relations team?

Genocea Biosciences' physical mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company's listed phone number is (617) 876-8191 and its investor relations email address is [email protected] The official website for Genocea Biosciences is www.genocea.com. Learn More about contacing Genocea Biosciences investor relations.